Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Semax

ACTH(4-10) analogue, Heptapeptide SEMAX

Quick Stats
Studies 172
Trials 37
Score 3
2002 pubmed

Therapy of peptic ulcer with semax peptide.

Ivanikov. I O IO; Brekhova. M E ME; Samonina. G E GE; Myasoedov. N F NF; Ashmarin. I P IP

Key Findings

  • Intranasal Semax (1% solution, 2‑4 drops, three times daily) was used alongside usual ulcer drugs
  • Ulcer healing after 14 days was 89.5% with Semax vs 30.8% in the control group
  • The authors call for larger clinical trials to confirm the anti‑ulcer effect

Practical Outcomes

  • If you have a refractory peptic ulcer and are already on standard therapy, a short course of intranasal Semax (as in the study) could boost healing, but only try it under a doctor's guidance. The protocol used was 2‑4 drops of a 1% solution three times a day for ten days. Evidence is still limited, so monitor symptoms closely and consider it an experimental adjunct.

Summary

A small study found that adding the nasal spray peptide Semax to standard ulcer medicines helped heal stubborn stomach ulcers much faster—about 90% of patients improved in two weeks versus only 31% without Semax. The peptide was given as a 1% solution, 2‑4 drops three times daily for ten days. More research is needed, but the result hints that Semax might be a useful add‑on for gut‑health issues.

Abstract

Experiments used is combination with traditional preparations (omeprasole, de-nol, and solcoseril), Semax peptide (Met-Glu-His-Phe-Pro-Gly-Pro) possessing nootropic and neuroprotective activity significantly promoted ulcer healing in patients with refractory peptic ulcers. On day 14 of treatment ulcer healing was observed in 89.5% patients receiving intranasal Semax (1% solution, 2-4 drops 3 times a day for 10 days) vs. 30.8% in the control group. Clinical studies of antiulcer activity of Semax in different combinations with usual antiulcer drugs are needed.

Study Information

Provider

pubmed

Year

2002

DOI

10.1023/a:1020621124776